M. Eneva

Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second‐line pembrolizumab in patients with non‐small‐cell lung cancer

M. Petrova, N. Conev, I. Donev, 2020, Clinical and experimental immunology.

Neutrophil to lymphocyte ratio as a potential predictive marker for treatment with pembrolizumab as a second line treatment in patients with non-small cell lung cancer.

M. Petrova, K. Koynov, N. Conev, 2020, Bioscience trends.

Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second‐line pembrolizumab in patients with non‐small‐cell lung cancer

M. Petrova, N. Conev, I. Donev, 2020, Clinical and experimental immunology.

Prevalence and prognosis of PIK3CA mutations in Bulgarian patients with metastatic breast cancer receiving endocrine therapy in first‐line setting

N. Conev, I. Donev, M. Radanova, 2023, Cancer reports.